retatrutide phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Incretin triple agonist retatrutide (LY3437943)

& Wadden, T

The model of the open state conformation was based on the cryo-EM structure of GLP-1GLP-1RGs (PDB: 5VAI) and the Fab7F38ECD complex of the Fab7F38GLP-1R crystal structure presented here, which were superimposed on their ECDs using PyMOL

With the 5 mg/mL concentration, every dose fits comfortably within a standard 1 mL insulin syringe

Consistency is key to maintaining a steady level of the medication in your bloodstream, which helps minimize side effects and maximize the appetite-suppression benefits

Sold for research purposes only.

While this supports weight loss, it can also leave you feeling low on energy